Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study
Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients with VLD has not been described and represents the aim of our study. Methods: International...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | JHEP Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555924001952 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218783877103616 |
|---|---|
| author | Valeria Perez-Campuzano Pierre-Emmanuel Rautou Thomas Marjot Michael Praktiknjo Edilmar Alvarado-Tapias Laura Turco Luis Ibáñez-Samaniego Carlos González-Alayón Ángela Puente Elba Llop Macarena Simón-Talero Carmen Álvarez-Navascués Thomas Reiberger Xavier Verhelst Luis Tellez Johanna Birte Bergmann Lara Orts Giuseppe Grassi Anna Baiges Payance Audrey Jonel Trebicka Candid Villanueva Maria Cristina Morelli Sam Murray Georgina Meacham Marc Luetgehetmann Julian Schulze zur Wiesch Juan-Carlos García-Pagán Eleanor Barnes Aurélie Plessier Virginia Hernández-Gea |
| author_facet | Valeria Perez-Campuzano Pierre-Emmanuel Rautou Thomas Marjot Michael Praktiknjo Edilmar Alvarado-Tapias Laura Turco Luis Ibáñez-Samaniego Carlos González-Alayón Ángela Puente Elba Llop Macarena Simón-Talero Carmen Álvarez-Navascués Thomas Reiberger Xavier Verhelst Luis Tellez Johanna Birte Bergmann Lara Orts Giuseppe Grassi Anna Baiges Payance Audrey Jonel Trebicka Candid Villanueva Maria Cristina Morelli Sam Murray Georgina Meacham Marc Luetgehetmann Julian Schulze zur Wiesch Juan-Carlos García-Pagán Eleanor Barnes Aurélie Plessier Virginia Hernández-Gea |
| author_sort | Valeria Perez-Campuzano |
| collection | DOAJ |
| description | Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients with VLD has not been described and represents the aim of our study. Methods: International, multicenter, prospective observational study in patients with VLD analyzing the incidence of COVID-19 infection after vaccination, severity of side effects, occurrence of thromboembolic events and hepatic decompensation. In a subgroup of patients, the humoral and cellular responses to vaccination were also analyzed. Results: A total of 898 patients from 14 European centers – part of the VALDIG network – were included, 872 (97.1%) patients received two vaccine doses (fully vaccinated), and 674 (75.1%) three doses. Of the total cohort, 151/898 had a COVID-19 infection prior to vaccination, of whom 9/151 (5.9%) were re-infected. Of the 747/898 patients who were not previously infected, 11.2% (84/747) were diagnosed with a COVID-19 infection during the study period. Two infected patients required intensive care unit admission and infection was fatal in two fully vaccinated patients. Adverse effects were reported in around 40% of patients, with local side effects being the most frequent. During the study period, 31 (3.5%) patients had thromboembolic events and 21 (2.3%) hepatic decompensations. No cases of vaccine-induced thrombocytopenia were reported. Vaccine immunogenicity was assessed in 36 patients; seroconversion reached 100% and IFNy T-cell responses significantly increased post two mRNA-1273 vaccine doses. Conclusion: Patients with VLD seem to have a preserved immune response to SARS-CoV-2 vaccination, which appears to be safe and effective in preventing severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, though the contribution of vaccination as a cofactor in VLD remains to be elucidated. Impact and implications:: Patients with vascular liver disease (VLD) are at increased risk of both SARS-CoV-2 infection and severe COVID-19 disease. The potential risks associated with vaccination against this infection need thorough investigation. Our research enhances the understanding of the effects of COVID-19 vaccination in patients with VLD, highlighting its good tolerability. Moreover, patients with VLD appear to have a preserved immune response to SARS-CoV-2 vaccination, providing protection against severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, and no cases of vaccine-induced thrombocytopenia were reported. |
| format | Article |
| id | doaj-art-856e9da0590e419eb52a0c8c7c221e7e |
| institution | OA Journals |
| issn | 2589-5559 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHEP Reports |
| spelling | doaj-art-856e9da0590e419eb52a0c8c7c221e7e2025-08-20T02:07:35ZengElsevierJHEP Reports2589-55592024-12-0161210119110.1016/j.jhepr.2024.101191Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter studyValeria Perez-Campuzano0Pierre-Emmanuel Rautou1Thomas Marjot2Michael Praktiknjo3Edilmar Alvarado-Tapias4Laura Turco5Luis Ibáñez-Samaniego6Carlos González-Alayón7Ángela Puente8Elba Llop9Macarena Simón-Talero10Carmen Álvarez-Navascués11Thomas Reiberger12Xavier Verhelst13Luis Tellez14Johanna Birte Bergmann15Lara Orts16Giuseppe Grassi17Anna Baiges18Payance Audrey19Jonel Trebicka20Candid Villanueva21Maria Cristina Morelli22Sam Murray23Georgina Meacham24Marc Luetgehetmann25Julian Schulze zur Wiesch26Juan-Carlos García-Pagán27Eleanor Barnes28Aurélie Plessier29Virginia Hernández-Gea30Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de InvestigacionsBiomèdiques August Pi iSunyer (IDIBAPS), Departament de Medicina I Ciències de la Salut - University of Barcelona, Barcelona. CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas). Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Rare Liver), SpainUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; Service d'Hépatologie, AP-HP, HôpitalBeaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, FranceNuffield Department of Medicine, University of Oxford, Oxford, United KingdomDepartment of Medicine B, University of Münster, Germany; Department of Medicine I, University Hospital Bonn, GermanyHospital de la Santa Creu i Sant Pau, Barcelona, SpainIRCCS AziendaOspedaliero-Universitaria di Bologna, ItalyHospital General Universitario Gregorio Marañon, Madrid, SpainHospital Universitario de Canarias, Tenerife, SpainHospital Marqués de Valdecilla, SpainHospital Puerta del Hierro, SpainLiverUnit, Digestive Diseases, Hospital Universitari Vall d’Hebron, VHIR, Vall d’Hebron Barcelona Hospital Campus, UAB, CIBERehd, Barcelona, SpainHospital Universitario Central de Asturias, SpainDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, AustriaDepartment of Gastroenterology and Hepatology, Ghent University Hospital, BelgiumHospital Universitario Ramón y Cajal, Madrid, SpainGerman Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, GermanyBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de InvestigacionsBiomèdiques August Pi iSunyer (IDIBAPS), Departament de Medicina I Ciències de la Salut - University of Barcelona, Barcelona. CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas). Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Rare Liver), SpainBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de InvestigacionsBiomèdiques August Pi iSunyer (IDIBAPS), Departament de Medicina I Ciències de la Salut - University of Barcelona, Barcelona. CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas). Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Rare Liver), SpainBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de InvestigacionsBiomèdiques August Pi iSunyer (IDIBAPS), Departament de Medicina I Ciències de la Salut - University of Barcelona, Barcelona. CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas). Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Rare Liver), SpainUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, FranceDepartment of Medicine B, University of Münster, GermanyHospital de la Santa Creu i Sant Pau, Barcelona, SpainIRCCS AziendaOspedaliero-Universitaria di Bologna, ItalyNuffield Department of Medicine, University of Oxford, Oxford, United KingdomNuffield Department of Medicine, University of Oxford, Oxford, United KingdomGerman Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, GermanyDepartment of Internal Medicine, University Medical Center Hamburg-Eppendorf, GermanyBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de InvestigacionsBiomèdiques August Pi iSunyer (IDIBAPS), Departament de Medicina I Ciències de la Salut - University of Barcelona, Barcelona. CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas). Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Rare Liver), SpainNuffield Department of Medicine, University of Oxford, Oxford, United KingdomUniversité Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, FranceBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de InvestigacionsBiomèdiques August Pi iSunyer (IDIBAPS), Departament de Medicina I Ciències de la Salut - University of Barcelona, Barcelona. CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas). Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Rare Liver), Spain; Corresponding author. Address: Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain. Tel.: +34932275400 (2209), Fax number: +34 932279856.Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients with VLD has not been described and represents the aim of our study. Methods: International, multicenter, prospective observational study in patients with VLD analyzing the incidence of COVID-19 infection after vaccination, severity of side effects, occurrence of thromboembolic events and hepatic decompensation. In a subgroup of patients, the humoral and cellular responses to vaccination were also analyzed. Results: A total of 898 patients from 14 European centers – part of the VALDIG network – were included, 872 (97.1%) patients received two vaccine doses (fully vaccinated), and 674 (75.1%) three doses. Of the total cohort, 151/898 had a COVID-19 infection prior to vaccination, of whom 9/151 (5.9%) were re-infected. Of the 747/898 patients who were not previously infected, 11.2% (84/747) were diagnosed with a COVID-19 infection during the study period. Two infected patients required intensive care unit admission and infection was fatal in two fully vaccinated patients. Adverse effects were reported in around 40% of patients, with local side effects being the most frequent. During the study period, 31 (3.5%) patients had thromboembolic events and 21 (2.3%) hepatic decompensations. No cases of vaccine-induced thrombocytopenia were reported. Vaccine immunogenicity was assessed in 36 patients; seroconversion reached 100% and IFNy T-cell responses significantly increased post two mRNA-1273 vaccine doses. Conclusion: Patients with VLD seem to have a preserved immune response to SARS-CoV-2 vaccination, which appears to be safe and effective in preventing severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, though the contribution of vaccination as a cofactor in VLD remains to be elucidated. Impact and implications:: Patients with vascular liver disease (VLD) are at increased risk of both SARS-CoV-2 infection and severe COVID-19 disease. The potential risks associated with vaccination against this infection need thorough investigation. Our research enhances the understanding of the effects of COVID-19 vaccination in patients with VLD, highlighting its good tolerability. Moreover, patients with VLD appear to have a preserved immune response to SARS-CoV-2 vaccination, providing protection against severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, and no cases of vaccine-induced thrombocytopenia were reported.http://www.sciencedirect.com/science/article/pii/S2589555924001952Vascular liver diseaseCOVID-19 vaccineportal thrombosis |
| spellingShingle | Valeria Perez-Campuzano Pierre-Emmanuel Rautou Thomas Marjot Michael Praktiknjo Edilmar Alvarado-Tapias Laura Turco Luis Ibáñez-Samaniego Carlos González-Alayón Ángela Puente Elba Llop Macarena Simón-Talero Carmen Álvarez-Navascués Thomas Reiberger Xavier Verhelst Luis Tellez Johanna Birte Bergmann Lara Orts Giuseppe Grassi Anna Baiges Payance Audrey Jonel Trebicka Candid Villanueva Maria Cristina Morelli Sam Murray Georgina Meacham Marc Luetgehetmann Julian Schulze zur Wiesch Juan-Carlos García-Pagán Eleanor Barnes Aurélie Plessier Virginia Hernández-Gea Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study JHEP Reports Vascular liver disease COVID-19 vaccine portal thrombosis |
| title | Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study |
| title_full | Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study |
| title_fullStr | Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study |
| title_full_unstemmed | Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study |
| title_short | Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study |
| title_sort | impact of sars cov 2 vaccination in patients with vascular liver diseases observations from a valdig multicenter study |
| topic | Vascular liver disease COVID-19 vaccine portal thrombosis |
| url | http://www.sciencedirect.com/science/article/pii/S2589555924001952 |
| work_keys_str_mv | AT valeriaperezcampuzano impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT pierreemmanuelrautou impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT thomasmarjot impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT michaelpraktiknjo impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT edilmaralvaradotapias impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT lauraturco impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT luisibanezsamaniego impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT carlosgonzalezalayon impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT angelapuente impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT elballop impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT macarenasimontalero impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT carmenalvareznavascues impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT thomasreiberger impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT xavierverhelst impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT luistellez impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT johannabirtebergmann impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT laraorts impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT giuseppegrassi impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT annabaiges impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT payanceaudrey impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT joneltrebicka impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT candidvillanueva impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT mariacristinamorelli impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT sammurray impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT georginameacham impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT marcluetgehetmann impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT julianschulzezurwiesch impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT juancarlosgarciapagan impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT eleanorbarnes impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT aurelieplessier impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy AT virginiahernandezgea impactofsarscov2vaccinationinpatientswithvascularliverdiseasesobservationsfromavaldigmulticenterstudy |